Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke

Intravenous alteplase or tissue plasminogen activator (tPA) has been the standard of care with proven efficacy for acute ischemic stroke for over a decade. Despite this, only a small fraction of potentially eligible stroke patients receive this medication. There seems to be a fear among practitioner...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruce, Nhu T., Neil, William P., Zivin, Justin A.
Formato: Texto
Lenguaje:English
Publicado: Current Science Inc. 2011
Materias:
Cerebrovascular Disease and Stroke
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085754/
https://www.ncbi.nlm.nih.gov/pubmed/21424751
http://dx.doi.org/10.1007/s11936-011-0122-0
Descripción
Sumario:Intravenous alteplase or tissue plasminogen activator (tPA) has been the standard of care with proven efficacy for acute ischemic stroke for over a decade. Despite this, only a small fraction of potentially eligible stroke patients receive this medication. There seems to be a fear among practitioners of legal repercussions as a result of an increased risk of intracerebral hemorrhage due to tPA. This review of legal cases involving tPA will show that instead, physicians are often found liable as a result of not treating with tPA.

Ejemplares similares